Gene expression changes induced by the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib in cancer cell lines.

Transcriptional changes were analyzed in two colorectal cancer, two pancreatic cancer, and one small cell lung cancer cell line following treatment with the BET inhibitor GSK525762 and/or the MEK inhibitor trametinib using Affymetrix Human Genome U133 Plus 2.0 Arrays. The RKO colon cancer cell line was treated with DMSO (control), 500nM GSK525762, 30nM trametinib, or a combination of two agents for 24 or 96 hours. The colon cancer cell line COLO 201 and the pancreatic cancer cell lines HPAF-II and BxPC-3 were treated with DMSO, 500nM GSK525762, trametinib (3nM for COLO 201; 10 nM for HPAF-II and BxPC-3), or a combination of two agents for 96 hours. The small cell lung cancer cell line NCI-H510 was treated with 1000nM GSK525762 for 24 or 96 hours. Two biological replicates are included for each treatment group.

本研究采用Affymetrix人基因组U133 Plus 2.0基因芯片，对经BET抑制剂（BET inhibitor）GSK525762和/或MEK抑制剂（MEK inhibitor）曲美替尼（trametinib）处理后的2株结直肠癌细胞系、2株胰腺癌细胞系及1株小细胞肺癌细胞系的转录组变化进行分析。针对RKO结肠癌细胞系，分别以二甲基亚砜（DMSO，对照组）、500nM GSK525762、30nM曲美替尼，或两药联合处理24小时或96小时。结肠癌细胞系COLO 201与胰腺癌细胞系HPAF-II、BxPC-3则分别以二甲基亚砜、500nM GSK525762、曲美替尼（COLO 201处理浓度为3nM，HPAF-II与BxPC-3处理浓度为10nM），或两药联合处理96小时。小细胞肺癌细胞系NCI-H510仅以1000nM GSK525762处理24小时或96小时。每个处理组均设置2次生物学重复。